Marvel Biosciences Corp MRVL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CAD 0.14
- Day Range
- CAD 0.14–0.16
- 52-Week Range
- CAD 0.01–0.19
- Bid/Ask
- CAD 0.15 / CAD 0.16
- Market Cap
- CAD 5.77 Mil
- Volume/Avg
- 158,571 / 55,081
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.56%
Company Profile
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer’s, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
Valuation
|
Metric
|
MRVL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MRVL
|
|---|---|
Quick Ratio | 0.41 |
Current Ratio | 0.43 |
Interest Coverage | −31.33 |
Quick Ratio
MRVL
Profitability
|
Metric
|
MRVL
|
|---|---|
Return on Assets (Normalized) | −335.71% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MRVL
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qyjhvpppyw | Wrtv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Njfswdtt | Twcmq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hmzjkjhmp | Cjhhx | $97.8 Bil | |
MRNA
| Moderna Inc | Gwgkkzgx | Cyx | $41.3 Bil | |
ARGX
| argenx SE ADR | Kymhjghjx | Ggpr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rksfcph | Vfhp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mvwnymps | Bytffp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yftlnhrjj | Hvvxl | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rnwgzhspjw | Fwdyyl | $12.5 Bil | |
INCY
| Incyte Corp | Nlcxvfbbr | Qnjygs | $11.6 Bil |